Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02685670 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma(MatchCART) | unknown | Phase 1 / Phase 2 | 20 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT02912754 | Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients | unknown | Phase 1 / Phase 2 | 36 | Sunnybrook Health Sciences CentreOTHER |
| 1 |
| Mar 13, 2017 |
| clinicaltrials |
| NCT02863302 | Reflexology: An Intervention for Acute Myeloid Leukemia(AML) Patients | unknown | N/A | 50 | Rambam Health Care CampusOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03053206 | A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia | unknown | Phase 2 | 84 | All India Institute of Medical SciencesOTHER | 0 | Feb 15, 2017 | clinicaltrials |
| NCT03045627 | Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients | unknown | Phase 2 | 120 | Shandong UniversityOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT03023384 | Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML(ICAML2015) | unknown | — | 547 | International Consortium on Acute LeukemiasOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT03035344 | Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia (ALL) | unknown | — | 25 | Aristotle University Of ThessalonikiOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT01226303 | Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia | unknown | Phase 3 | 300 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 1 | Jan 26, 2017 | clinicaltrials |
| NCT02979548 | Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy | unknown | Phase 3 | 116 | Dr Atul SharmaOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT03027739 | CART-19 Cells For MRD Positive CD19+ ALL(CCFMPCA) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT03026842 | Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) | unknown | Phase 4 | 180 | The First Hospital of Jilin UniversityOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT03022747 | Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol | unknown | Phase 2 | 60 | Vastra Gotaland RegionOTHER_GOV | 2 | Jan 16, 2017 | clinicaltrials |
| NCT01828489 | Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years(AML2012) | unknown | Phase 3 | 300 | Vastra Gotaland RegionOTHER_GOV | 9 | Jan 10, 2017 | clinicaltrials |
| NCT02990104 | First Report, Five Years Experience of the Acute Leukemia Work Group(PR-GTLA) | unknown | — | 500 | Mexican Agrupation for Hematology StudyOTHER | 1 | Dec 13, 2016 | clinicaltrials |
| NCT02985372 | Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia | unknown | Phase 3 | 30 | Chunyan JiOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02892695 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02944162 | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02975115 | Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization | unknown | — | 102 | Seoul St. Mary's HospitalOTHER | 0 | Nov 29, 2016 | clinicaltrials |
| NCT02968472 | A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia | unknown | Phase 1 | 30 | The First People's Hospital of YunnanOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02949570 | Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study(ICT10) | unknown | Phase 2 | 54 | Hybrigenics CorporationINDUSTRY | 1 | Oct 31, 2016 | clinicaltrials |
| NCT02819583 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Oct 25, 2016 | clinicaltrials |
| NCT02810223 | Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Beijing Sanwater Biological Technology Co., Ltd.INDUSTRY | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02432872 | Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years | unknown | N/A | 300 | Jianxiang WangUNKNOWN | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02432911 | Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old | unknown | N/A | 300 | Jianxiang WangUNKNOWN | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02894645 | Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | unknown | Phase 4 | 500 | National University Hospital, SingaporeOTHER | 2 | Sep 30, 2016 | clinicaltrials |
| NCT02027064 | Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT | unknown | Phase 4 | 40 | Peking University People's HospitalOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT02568241 | Interferon-α After DLI for the Prevention of Relapse(IDPR-HSCT) | unknown | Phase 1 / Phase 2 | 42 | Peking University People's HospitalOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT02895412 | Infection and Tumour Antigen Cellular Therapy(INTACT-WT1) | unknown | Phase 1 | 20 | University of SydneyOTHER | 1 | Sep 9, 2016 | clinicaltrials |
| NCT02846584 | a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies | unknown | Phase 2 | 100 | Southwest Hospital, ChinaOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT01758367 | Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT02883036 | Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia | unknown | — | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT02859948 | A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 9, 2016 | clinicaltrials |
| NCT02860598 | Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy(EPREX/LAM-ALLO) | unknown | — | 104 | Hospices Civils de LyonOTHER | 1 | Aug 9, 2016 | clinicaltrials |
| NCT02456350 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02766868 | Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL | unknown | Phase 2 | 20 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02848183 | Optimal Treatment Strategy Based on for Pediatric AML | unknown | Phase 2 | 350 | Samsung Medical CenterOTHER | 1 | Jul 28, 2016 | clinicaltrials |
| NCT01146262 | Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)(CD lam) | unknown | Phase 1 / Phase 2 | 5 | Nantes University HospitalOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT01484171 | HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia | unknown | Phase 3 | 50 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02171117 | Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia(IMCG-EAML) | unknown | Phase 3 | 196 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02828774 | Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia | unknown | — | 30 | Assuta Medical CenterOTHER | 0 | Jul 12, 2016 | clinicaltrials |
| NCT02619071 | ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia(CeGAL) | unknown | N/A | 87 | Institut Paoli-CalmettesOTHER | 1 | Jun 28, 2016 | clinicaltrials |
| NCT02813837 | Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies | unknown | N/A | 30 | Innovative Cellular Therapeutics Co., Ltd.OTHER | 1 | Jun 28, 2016 | clinicaltrials |
| NCT02315118 | Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 18 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02784561 | Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | unknown | Phase 4 | 80 | Chinese PLA General HospitalOTHER | 0 | May 27, 2016 | clinicaltrials |
| NCT02757586 | Treatment of Chronic Lymphocytic Leukemia | unknown | — | 70 | Peking University People's HospitalOTHER | 0 | May 13, 2016 | clinicaltrials |
| NCT01690065 | Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML(NICE-BORA) | unknown | Phase 2 | 46 | Ulsan University HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT02422719 | Radotinib as 3rd or Later Line Therapy in CP-CML(REVITAL) | unknown | Phase 2 | 73 | Ulsan University HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01501708 | Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection | unknown | Phase 2 | 55 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 10, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Mar 16, 2017source: clinicaltrials